EphA2-ILs-DTXp in combination with gemcitabine induced significantly more tumor regression than gemcitabine monotherapy (Figure 5B) (ANOVA and post-hoc Tukey HSD; Combination vs. Gem: p < 0.05) and led to a significant extension of survival when compared to either drug alone or to equitoxic combination of gemcitabine and free DTX (Figure 5C) (Log-Rank Prob > ChiSq Survival: EphA2-ILs-DTXp/Gem vs. Gem p < 0.05; EphA2-ILs-DTXp/Gem vs. EphA2-ILs-DTXp p < 0.05; EphA2-ILs-DTXp/Gem vs. DTX/Gem p < 0.05). This evidence concerns the gene EPHA2 and neoplasm.